Simba Gill - 07 May 2023 Form 4/A - Amendment Insider Report for Evelo Biosciences, Inc.

Role
President & CEO, Director
Signature
/s/ Marella Thorell, Attorney-in-Fact for Balkrishan (Simba) Gill, Ph.D.
Issuer symbol
EVLO on OTC
Transactions as of
07 May 2023
Net transactions value
$0
Form type
4/A - Amendment
Filing time
10 May 2023, 17:11:53 UTC
Date Of Original Report
09 May 2023
Previous filing
09 Feb 2023
Next filing
10 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVLO Restricted Stock Units Options Exercise $0 -23,437 -6.2% $0.000000 351,563 07 May 2023 Common Stock 23,437 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2 The RSUs vest in sixteen (16) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the fourth anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. The RSUs have no expiration date.

Remarks:

This Form 4/A is being filed to disclose the disposition of 23,437 RSUs. Column 5 of Table II in the Form 4 filed on May 9, 2023 inadvertently and improperly showed that these securities were acquired. Column 9 of Table II remains unchanged from the May 9, 2023 filing.